[Malignant lymphoma].
Based on the systematic improvements in treatment over recent decades, more than 70% of children and adolescents with non-Hodgkin lymphoma will survive at least 5 years with standard chemotherapy. This report highlights several advances in treatment for each histologic subtype of childhood non-Hodgkin lymphoma, focusing on published results of clinical trials from European and North American study groups.